« Return to News | Study Conduct

Initiative to double survival rate for pancreatic cancer calls for more clinical trial participants

Monday, January 9, 2012 09:17 AM

The Pancreatic Cancer Action Network is calling for increased participation in clinical trials as part of its initiative to double the survival rate of pancreatic cancer by 2020.

Currently only three FDA approved drugs to treat pancreatic adenocarcinoma, the most common type of pancreatic cancer, are available. Although many other clinical trials are planned or in process, participant numbers are low. The Pancreatic Cancer Action Network stresses that increased participation, and in turn increased clinical trials, are vital to meeting its 2020 goal.

The organization also encouraged patients with pancreatic cancer to consider clinical trials when exploring treatment options.

“Through participation in clinical trials, patients have access to cutting edge research and are taking an active role in advancing pancreatic cancer research. Clinical trials pave the way to therapeutic breakthroughs,” said Julie Fleshman, president and CEO of the Pancreatic Cancer Action Network.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013
Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings
Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving
Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.